Meeting
2020 ASCO Virtual Scientific Program
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.
Authors
Elgene Lim
St. Vincent's Hospital, University of New South Wales, Darlinghurst, Australia
Elgene Lim , Komal L. Jhaveri , Meritxell Bellet , Valentina Boni , Jose Manuel Perez Garcia , Laura Estevez , Aditya Bardia , Nicholas C. Turner , Rafael Villanueva , Sara Lopez-Tarruella Cobo , Seock-Ah Im , Sung-Bae Kim , Mary R. Gates , Sharareh Monemi , Ya-Chi Chen , Heather Moore , Sherene Loi , Joohyuk Sohn , Jose Alejandro Perez-Fidalgo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03332797
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1023)
DOI
10.1200/JCO.2020.38.15_suppl.1023
Abstract #
1023
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2022 ASCO Annual Meeting
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
First Author: Komal L. Jhaveri
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao